Global HER2 ADC Drugs Market Growth 2024-2030

Global HER2 ADC Drugs Market Growth 2024-2030

The HER2-targeted antibody–drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) represent a novel class of therapeutics in breast cancer. These drugs augment monoclonal antibodies with a cytotoxic payload, which is attached by a linker, forming the basic structure of an ADC.

The global HER2 ADC Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “HER2 ADC Drugs Industry Forecast” looks at past sales and reviews total world HER2 ADC Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected HER2 ADC Drugs sales for 2024 through 2030. With HER2 ADC Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HER2 ADC Drugs industry.

This Insight Report provides a comprehensive analysis of the global HER2 ADC Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HER2 ADC Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global HER2 ADC Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HER2 ADC Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HER2 ADC Drugs.

United States market for HER2 ADC Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for HER2 ADC Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for HER2 ADC Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key HER2 ADC Drugs players cover Daiichi Sankyo, Genentech, Inc.(Roche), AstraZeneca, RemeGen, MacroGenics, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of HER2 ADC Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
T-DM1（Kadcyla，Trastuzumab emtansine）
T-DXd（DS-8201，Enhertu，Trastuzumab deruxtecan）
RC48（Disitamab vedotin）

Segmentation by Application:
Hospitals
Clinic
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Daiichi Sankyo
Genentech, Inc.(Roche)
AstraZeneca
RemeGen
MacroGenics
Takeda
Biokin Pharmaceutical
BioNTech(Yingen Biopharmaceutical)
CSPC Pharmaceutical Group
Hengrui Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global HER2 ADC Drugs market?

What factors are driving HER2 ADC Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do HER2 ADC Drugs market opportunities vary by end market size?

How does HER2 ADC Drugs break out by Type, by Application?



Please note: The report will take approximately 2 business days to prepare and deliver.